New Therapy for Advanced RCC

FDA approves combination IO therapy of Opdivo and Yervoy for treating advanced kidney cancer patients in the first-line setting

Learn more
Photo Credit: Kidney Cancer Researchers at UTSW Medical Center

Patient Voices

Research

Donate

Latest Post

KCCURE HAILS FDA APPROVAL OF FIRST COMBINATION IMMUNOTHERAPY FOR FIRST LINE RENAL CELL CARCINOMA

“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder an...Read More

Recent Posts

Voice of Kidney Cancer – Deb Gottsleben

Deb Gottsleben is co-chair of the KCCure Patient Advisory Board and a passionate advocate for better care for patients with newly diagnosed renal tumors.

Voice of Kidney Cancer – Paul Vollmer

Today’s Voice of Kidney Cancer is a truly unique story of spontaneous remission. For the skeptics among us it is a story that one would expect to find in the se...Read More

Tweets

Lost Password

Register

Subscribe for updates!

Sign up to receive the KCCure newsletter.

* indicates required
×